Researchers delve into the challenges of treating T-Prolymphocytic Leukemia due to limited options and high relapse rates. Chromosomal aberrations and genomic alterations play a crucial role in the aggressive nature of this disease.

Dr. Michael Goldstein discusses targeting H3K27me3 loss in pediatric brain tumors, particularly DMG, ependymoma, and medulloblastoma. High relapse rates in pediatric cancer challenge current treatments, with radiotherapy as a primary modality. H3K27 tri-methylation is a key epigenetic trait in these brain tumors. Exploring the role of H3K27-Me3 in treatment response and survival rates.

Exploring the significance of ER expression in DCIS, a pivotal study showed lack of ER linked to 3-fold risk of recurrence. ER expression in DCIS is multi-clonal with important clinical implications. Some ER-positive DCIS cases also contained ducts lacking ER expression.

Exploring the link between obesity, diabetes, and lung cancer, scientists are investigating using Metformin to target all three issues. The podcast discusses the potential of Metformin's therapeutic properties and explores the obesity paradox in chronic illnesses and aging.

Exploring the potential therapeutic role of KIAA0930 in cancer cachexia, a new study identifies it as a candidate factor for inducing muscle atrophy in cancer cells, offering hope for developing anti-cachexia therapies

New research paper on assessing p300/CBP in circulating tumor cells. Connection between SIRT2 deacetylation and p300 acetylation in prostate cancer. Use of Exclusion-based Sample Preparation to isolate CTCs. Staining optimization reveals expression of acetyl-p300 and acetyl-H3K18.

Explore a new editorial paper discussing a novel therapeutic approach against melanoma by targeting Hedgehog signaling and BRD4. Learn about the limitations of current SMO inhibitors, the potential of non-canonical HH/GLI signaling, and the researchers' proposal for improving therapeutic response rates.

Exploring a rare case of a 15-year-old boy with Intrathoracic Synovial Sarcoma and BRAF V600E mutation, showcasing the benefits of molecular testing and targeted treatment with a BRAF inhibitor for better patient outcomes

The podcast explores the crucial role of Ras in cancer development, focusing on how inhibitors can target Ras mutations in pancreatic, colorectal, and lung cancers. Advances in engineering Ras binders using protein scaffolds, experimental evolution, and computational techniques are highlighted for more effective treatment. Intracellular protein delivery techniques like fusion with CPPs and nanoparticle coupling offer innovative strategies for precise Ras inhibitor delivery in cells, enhancing targeted cancer treatments.

Exploring the use of cetuximab with radiotherapy for locally advanced cutaneous squamous cell skin cancer, with high response rates and minimal toxicity in a retrospective study of 18 patients.